These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 12868201)

  • 21. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
    Hermann M; Camici G; Fratton A; Hurlimann D; Tanner FC; Hellermann JP; Fiedler M; Thiery J; Neidhart M; Gay RE; Gay S; Lüscher TF; Ruschitzka F
    Circulation; 2003 Nov; 108(19):2308-11. PubMed ID: 14597594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COX-2-specific inhibitors and the kidney: effect on hypertension and oedema.
    Whelton A
    J Hypertens Suppl; 2002 Sep; 20(6):S31-5. PubMed ID: 12683425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention.
    Kismet K; Akay MT; Abbasoglu O; Ercan A
    Cancer Detect Prev; 2004; 28(2):127-42. PubMed ID: 15068837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of rheumatoid arthritis and osteoarthritis with COX-2-selective inhibitors: a managed care perspective.
    Hochberg MC
    Am J Manag Care; 2002 Nov; 8(17 Suppl):S502-17. PubMed ID: 12458820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Specific inhibitors of cyclooxygenase type 2] ].
    Tomasová-Studýnková J
    Vnitr Lek; 2002 May; 48(5):403-8. PubMed ID: 12061207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiinflammatory and analgesic efficacy of COX-2 specific inhibition: from investigational trials to clinical experience.
    Bensen WG
    J Rheumatol Suppl; 2000 Oct; 60():17-24. PubMed ID: 11032098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Adverse effect-free analgesia. New COX-2 inhibitor is even more selective].
    MMW Fortschr Med; 2003 May; 145(18):54. PubMed ID: 12808824
    [No Abstract]   [Full Text] [Related]  

  • 28. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib.
    Goldstein JL; Eisen GM; Agrawal N; Stenson WF; Kent JD; Verburg KM
    Aliment Pharmacol Ther; 2004 Sep; 20(5):527-38. PubMed ID: 15339324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
    Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful use of cyclooxygenase-2 inhibitor in a patient with aspirin-induced asthma.
    Marks F; Harrell K; Fischer R
    South Med J; 2001 Feb; 94(2):256-7. PubMed ID: 11235048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The coxibs, selective inhibitors of cyclooxygenase-2.
    Killen JP
    N Engl J Med; 2001 Dec; 345(23):1708; author reply 1709. PubMed ID: 11759656
    [No Abstract]   [Full Text] [Related]  

  • 32. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?
    Jüni P; Rutjes AW; Dieppe PA
    BMJ; 2002 Jun; 324(7349):1287-8. PubMed ID: 12039807
    [No Abstract]   [Full Text] [Related]  

  • 33. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells.
    Niederberger E; Manderscheid C; Grösch S; Schmidt H; Ehnert C; Geisslinger G
    Biochem Pharmacol; 2004 Jul; 68(2):341-50. PubMed ID: 15194006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. COX-2-selective inhibitors (COXIBs): gastrointestinal safety.
    Pronai L; Hritz I; Molnar B; Herszenyi L; Tulassay Z
    Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):23-30. PubMed ID: 14552701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Tolerable pain therapy in rheumatism saves long-term costs. Despite this most COX-2 candidates receive conventional NSAID therapy].
    MMW Fortschr Med; 2003 Jul; 145(29-30):61. PubMed ID: 12958786
    [No Abstract]   [Full Text] [Related]  

  • 36. Adverse Drug Events Involving COX-2 Inhibitors.
    Verrico MM; Weber RJ; McKaveney TP; Ansani NT; Towers AL
    Ann Pharmacother; 2003 Sep; 37(9):1203-13. PubMed ID: 12921500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Current status of COX II inhibitors in therapy of rheumatoid arthritis in comparison with conventional non-steroidal anti-inflammatory agents. Attempt at an evaluation with regard to evidence-based medicine].
    Krüger K
    Z Rheumatol; 2001 Dec; 60(6):481-4. PubMed ID: 11826746
    [No Abstract]   [Full Text] [Related]  

  • 38. Persistence with COX-2 inhibitors in managed care: an analysis of claims data.
    Harley C; Wagner S
    Manag Care Interface; 2003 Oct; 16(10):38-45. PubMed ID: 14606259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib.
    Hinz B; Dormann H; Brune K
    Arthritis Rheum; 2006 Jan; 54(1):282-91. PubMed ID: 16385545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Analgesic effects of cyclooxygenase 2 inhibitors].
    Jayr C
    Bull Cancer; 2004 May; 91 Spec No():S125-31. PubMed ID: 15239341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.